Phase 2 Leukaemia Trial, Recruiting NCT07362095 Sponsor: Zhujiang Hospital Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT07362095
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with acute leukemia
  • You have already received a stem cell transplant from a donor (known as an allogeneic stem cell transplant)
  • Your doctors expect you to live for more than 3 months from the time you sign the consent form
  • You are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests, and you can give written consent
  • If you are a woman who could become pregnant, you must have a negative pregnancy test before joining, and both men and women who could have children must agree to use effective birth control throughout the study (women who have had surgery to prevent pregnancy or have been through menopause for at least 2 years do not need the pregnancy test)
  • Your hemoglobin (a measure of red blood cells) level is below 80 g/L, meaning you have significant anaemia

Who may not be able to join:

  • Your kidneys, heart, lungs, or liver are not working well enough (specific blood and test results will be checked — confirm with trial site)
  • You have high blood pressure that is not well controlled by medication, or you have a history of a severe high blood pressure crisis
  • You have had another type of cancer in the past 5 years (though certain minor or early-stage skin, cervical, breast, or prostate cancers may still allow you to join — confirm with trial site)
  • You have had a major operation in the 8 weeks before joining, or have not fully recovered from any previous surgery
  • You have had a stroke, mini-stroke, blood clots in the veins or arteries, or a lung clot in the 6 months before joining (minor superficial vein inflammation does not count)
  • You have uncontrolled epilepsy, a history of bleeding or reduced blood flow in the brain, or another active brain or nervous system condition
  • You have had a serious heart problem in the 6 months before joining, such as a heart attack, severe or uncontrolled heart failure, or an uncontrolled irregular heartbeat
  • You have an active infection (such as a fungal, bacterial, or viral infection) that is not under control
  • You have HIV, active hepatitis B, or active hepatitis C
  • You have a history of a condition called pure red cell aplasia, or have developed antibodies against erythropoietin (a protein that helps make red blood cells) — (confirm with trial site)
  • You are taking a medication or have a condition that might affect how the study results are interpreted
  • You are known to be allergic to the study drug (luspatercept) or any of its ingredients

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhao Liang, Doctor, Zhujiang Hosptial of Southern Medical University

Phone: 86 13631451531

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Zhujiang Hospital
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of patients with reduced transfusion requirement

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov